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The Belgian national EPTRI Joint Research Unit (JRU) involves
academic research organisations and hospitals from Flanders,
Brussels and Wallonia
The Belgian JRU partners will gather complementary scientific and
technological competencies in the different EPTRI thematic research
platforms:
• Paediatric medicines discovery: several preclinical models have
been developed within this consortium: placental and umbilical
cord and 3D organoid cell cultures from paediatric samples;
juvenile animal models such as the rabbit BPD model, juvenile
Göttingen minipig, juvenile conventional pig model and
developmental zebrafish model
• Paediatric biomarkers and biosamples: identification,
characterisation and validation of biomarkers used as prognostic
tools, safety markers and diagnostic tools in paediatric diseases
• Developmental pharmacology: including PK bioavailability/
bioequivalence studies, population PK/PD analysis and PK/PD
modelling
• Paediatric medicines formulations and medical devices:
including regulatory knowledge
The partners will ensure a strong liaison with other RIs and networks
such as the BBMRI-ERIC for paediatric biobanking, the IMI
conect4children network for paediatric clinical trials and the Belgian
Paediatric Clinical Research Network (BPCRN)
• Minors represent 20% of the population of Europe
• Their care should be one of the most important priorities
• Paediatricians often give drugs designed for adults to children in
an ‘off-label’ prescription in 50% up to 90% of cases depending
on disease and age
• Children often do not respond to medications in the same way as
adults and can have different and more serious drug adverse
reactions
• To address this societal need, we need to develop medications
specifically designed and approved for children
• The European Paediatric Translational Research Infrastructure
(EPTRI) Belgian Joint Research Unit (JRU) (Figure 1) will create a
new research infrastructure entirely dedicated to translational
paediatric research and aims to stimulate and accelerate
innovative drug development processes for children
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• We propose an integrated paediatric research system that links
together EPTRI Belgium with landmark RIs, conect4children, the
BPCRN and institutions that provide services to paediatric
research
• This integrated system can provide: expertise, experienced
facilities and practical support for pre-clinical and clinical
paediatric research in Belgium and Europe. To share the
understanding of patients’ needs and concerted efforts in
paediatric research will further enhance the health of children
• The overarching goal of EPTRI Belgian JRU is to create a
framework for basic and translational paediatric research to
facilitate the development of new innovative medicines for
children
• EPTRI Belgian JRU has the goal to move to a new approach
characterized by medicines specifically designed to address the
needs of children and to reduce the existing gap on medicines
availability for babies, children and adolescents
